Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.

Ragonese, M., Grottoli, S., Maffei, P., Alibrandi, A., Ambrosio, M.R., Arnaldi, G., et al. (2018). How to improve effectiveness of pegvisomant treatment in acromegalic patients. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 41(5), 575-581 [10.1007/s40618-017-0773-0].

How to improve effectiveness of pegvisomant treatment in acromegalic patients

Arnaldi, G;
2018-01-01

Abstract

Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.
2018
Ragonese, M., Grottoli, S., Maffei, P., Alibrandi, A., Ambrosio, M.R., Arnaldi, G., et al. (2018). How to improve effectiveness of pegvisomant treatment in acromegalic patients. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 41(5), 575-581 [10.1007/s40618-017-0773-0].
File in questo prodotto:
File Dimensione Formato  
s40618-017-0773-0.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 524.46 kB
Formato Adobe PDF
524.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/620785
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact